Skip to main content
. Author manuscript; available in PMC: 2022 Sep 3.
Published in final edited form as: Biochem Pharmacol. 2020 Dec 14;184:114368. doi: 10.1016/j.bcp.2020.114368

Fig. 3.

Fig. 3.

Pharmacological concentration response curves of potential PXR agonists. The hPXR-Luc HepG2 stable cells were treated with multiple concentrations of RIF (a), benidipine (b), dasatanib (c), etomidoline (d), FR167356 (e), lacidipine (f), liranaftate, (g), mosapride (h), prodiamine (i), thiazopyr (j), tolindate (k), and zosuquidar (l) and co-treated with DMSO, 0.5 μM SPA70, or 0.75 μM SPA70. The efficacy of each compound was compared to the positive control, RIF (100% = RIF activity). Each curve represents the mean ± SD of three separate experiments.